Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
The Post ASH Significant Highlights meeting taking place in London is an essential event for all professionals working in haematology, providing an overview of the most impactful and innovative clinical and scientific data from the ASH 2024 conference. Tailored to a UK audience, the programme spans across two days and covers a range of haematological malignancies, with expert-led sessions, discussions, and networking opportunities.
Day 1 focuses on lymphomas, including updates on CLL, low-grade lymphomas, Hodgkin lymphoma, and high-grade lymphomas, as well as insights into new treatment options, CAR-T therapies, and sequencing strategies.
Day 2 highlights advancements in acute and chronic leukaemias, multiple myeloma, and myeloproliferative neoplasms. Discussions will explore topics such as frailty in multiple myeloma, new developments in CAR-T and bispecifics, and the latest in amyloidosis, MPN, and autoimmune cytopenias.
–
